
Jennifer Cautela

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7796000/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity. Circulation, 2017, 136, 2085-2087.	1.6	364
2	Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardioâ€Oncology Guidelines. Journal of the American Heart Association, 2020, 9, e018403.	3.7	149
3	Takotsubo-Like Syndrome in CancerÂPatients Treated With ImmuneÂCheckpoint Inhibitors. JACC: Cardiovascular Imaging, 2018, 11, 1187-1190.	5.3	82
4	Etiology of Pericarditis in a Prospective Cohort of 1162 Cases. American Journal of Medicine, 2015, 128, 784.e1-784.e8.	1.5	69
5	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis. JAMA Cardiology, 2021, 6, 1329.	6.1	64
6	Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. , 2020, 8, e001887.		45
7	Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 312-320.	3.0	42
8	Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event. Canadian Journal of Cardiology, 2020, 36, 476-481.	1.7	40
9	Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. International Journal of Cardiology, 2016, 224, 366-375.	1.7	32
10	Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey. International Journal of Cardiology, 2017, 241, 387-392.	1.7	27
11	Prevalence and characteristics of coronary artery disease in heart failure with preserved and mid-range ejection fractions: A systematic angiography approach. Archives of Cardiovascular Diseases, 2018, 111, 109-118.	1.6	23
12	Management of Immune Checkpoint Inhibitor–Induced Myocarditis. JACC: CardioOncology, 2021, 3, 157-161.	4.0	22
13	Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor–induced Myocarditis. Radiology, 2022, 303, 512-521.	7.3	21
14	Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. European Journal of Internal Medicine, 2019, 68, 71-75.	2.2	16
15	Controlled sedation with midazolam and analgesia with nalbuphine to alleviate pain in patients undergoing subcutaneous implantable cardioverter defibrillator implantation. Journal of Interventional Cardiac Electrophysiology, 2017, 49, 191-196.	1.3	14
16	Wearable cardioverter defibrillator: Bridge or alternative to implantation?. World Journal of Cardiology, 2017, 9, 531.	1.5	11
17	Ventricular Arrhythmia Occurrence and Compliance in Patients Treated With the Wearable Cardioverter Defibrillator Following Percutaneous Coronary Intervention. Heart Lung and Circulation, 2018, 27, 984-988.	0.4	7
18	Cancer Therapies and Vascular Toxicities. Current Treatment Options in Oncology, 2022, 23, 333-347.	3.0	6

JENNIFER CAUTELA

#	Article	IF	CITATIONS
19	Prehospital and in-hospital course of care for patients with acute heart failure: Features and impact on prognosis in "real lifeâ€. Archives of Cardiovascular Diseases, 2017, 110, 72-81.	1.6	5
20	Dynamic iron status after acute heart failure. Archives of Cardiovascular Diseases, 2019, 112, 410-419.	1.6	5
21	Device-Related Thrombus After Left Atrial Appendage Occlusion With the Amulet Device. Heart Lung and Circulation, 2019, 28, 1683-1688.	0.4	4
22	Impact of the time-to-treatment concept on the outcome of acute heart failure: A pilot study. Archives of Cardiovascular Diseases, 2018, 111, 270-275.	1.6	3
23	Rational and Design of the SIMULATOR Study: A Multicentre Randomized Study to Assess the Impact of SIMULation-bAsed Training on Transoesophageal echocardiOgraphy leaRning for Cardiology Residents. Frontiers in Cardiovascular Medicine, 2021, 8, 661355.	2.4	3
24	Response to the letter: The high burden of coronary artery disease in heart failure with preserved ejection fraction. Archives of Cardiovascular Diseases, 2018, 111, 227.	1.6	1
25	Response by Thuny et al to Letter Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity― Circulation, 2018, 137, 2423-2424.	1.6	0